Donafenib and immunotherapy with TACE or HAIC for liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study looks at combining donafenib (a targeted therapy) with an immunotherapy drug (PD-1/L1 inhibitor) and either TACE or HAIC (two types of minimally invasive treatments for liver tumors) as a first treatment for people with liver cancer that cannot be removed by surgery. It aims to see how well this combination works and how safe it is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with liver cancer that cannot be surgically removed.
- You are at least 18 years old.
- You have not had any other cancer treatments before starting this combination therapy.
- Your overall health is good enough for daily activities (ECOG score 0 or 1).
- Your liver function is well enough (Child-Pugh class A or B).
- Your blood counts and kidney/liver lab tests are within certain limits (detailed in the full eligibility).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if giving a combination of drugs (apatinib and camrelizumab) along with a procedure called TACE before surgery can help treat a certain type of liver cancer. The goal is to shrink the tumor before the operation to improve outcomes.
This trial tests a drug called Donafenib (a targeted therapy) taken after surgery to see if it can prevent liver cancer from coming back in people at high risk of recurrence.
This trial tests a combination of three treatments: a special way to deliver chemotherapy directly to the liver (FOLFOX-HAIC), plus two oral and injectable immunotherapy drugs (Donafenib and Pucotenlimab). It is for people with advanced liver cancer (HCC) who have not had prior systemic therapy and whose tumors cannot be surgically removed.
This trial tests a combination of the targeted drug donafenib, immunotherapy, and local treatments (like chemo delivered directly to the liver) for people with liver cancer that cannot be removed by surgery and has stopped responding to previous treatments. The goal is to see if this new combination can shrink tumors or slow the disease.
This study tests a new way to treat liver cancer that can't be removed with surgery. It combines a targeted drug (donafenib) with a procedure called E-TACE, which delivers chemotherapy directly to the tumor. The goal is to see if this combination works better than standard treatments.
This trial tests a new targeted therapy called donafenib for patients with advanced hepatocellular carcinoma (liver cancer) that cannot be surgically removed. The drug may help slow or shrink the cancer in patients who haven't received systemic chemotherapy before.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.